Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial
AB Gottlieb, R Evans, S Li, LT Dooley, CA Guzzo… - Journal of the American …, 2004 - Elsevier
BACKGROUND: Tumor necrosis factor–α is a key mediator in the pathogenesis of psoriasis.
Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-α,
blocking its biologic activity. OBJECTIVE: The purpose of this study was to access the
efficacy and safety of infliximab induction therapy for patients with severe plaque psoriasis.
METHODS: In this multicenter, double-blind, placebo-controlled trial, 249 patients with
severe plaque psoriasis were randomly assigned to receive intravenous infusions of either 3 …
Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-α,
blocking its biologic activity. OBJECTIVE: The purpose of this study was to access the
efficacy and safety of infliximab induction therapy for patients with severe plaque psoriasis.
METHODS: In this multicenter, double-blind, placebo-controlled trial, 249 patients with
severe plaque psoriasis were randomly assigned to receive intravenous infusions of either 3 …